老年性痴呆抗体药物研究进展

老年性痴呆(Alzhimer's disease，AD)是一种渐进性神经退化性疾病，其主要表现为记忆功能衰减及识别能力障碍，同时伴有各种神经症状和行为障碍，具有非常高的发病率，目前还没有特异性治疗药物。随着世界人口老龄化，AD发病率逐年增高，成为本世纪威胁人类健康最严重的疾病之一。近年来AD的发病机理和药物研究方面都有突破性进展，尤其是制备针对β淀粉样蛋白（amyloid beta protein，Aβ）特异性抗体药物成为AD治疗极具价值的途径。本文主要对以Aβ为主的AD发病机理和针对Aβ的抗体药物的治疗机制、研究现状及进展进行综述，为进一步研发AD治疗药物提供参考。

Immunotherapy of Alzheimer's Disease Mediated by Anti-A Antibodies

Alzhimer's disease (AD) is the most prevalent neurodegenerative disease in the elder. The disease is characterized by memory impairment and cognitive obstacle. The current treatments of AD provide only symptomatic relief and are practically inefficient. With the advancing ageing population in the world,AD is becoming one of the most severe diseases that damages humankind's health. Now, anti-Aβ antibodies have been suggested as a potential therapeutic strategy for the treatment of AD. In this paper, we summarize the recent progress in pathogenesis based on the Aβ hypothesis, possible mechanisms of Aβ-clearance by anti-Aβ antibody, and potential methods to prepare anti-Aβ antibody, etc.